Targeting systemic and gut microbial metabolism in ER < sup > + < /sup > breast cancer

Trends Endocrinol Metab. 2024 Jan 13:S1043-2760(23)00273-4. doi: 10.1016/j.tem.2023.12.008. Online ahead of print.ABSTRACTEstrogen receptor-positive (ER+) breast tumors have a better overall prognosis than ER- tumors; however, there is a sustained risk of recurrence. Mounting evidence indicates that genetic and epigenetic changes associated with resistance impact critical signaling pathways governing cell metabolism. This review delves into recent literature concerning the metabolic pathways regulated in ER+ breast tumors by the availability of nutrients and endocrine therapies and summarizes research on how changes in systemic and gut microbial metabolism can affect ER activity and responsiveness to endocrine therapy. As targeting of metabolic pathways using dietary or pharmacological approaches enters the clinic, we provide an overview of the supporting literature and suggest future directions.PMID:38220576 | DOI:10.1016/j.tem.2023.12.008
Source: Trends in Endocrinology and Metabolism: TEM - Category: Endocrinology Authors: Source Type: research